The alarming rise of medicalisation in India
Note on sourcing: WebSearch (2 queries, restricted where possible to gov.in/who.int/pib domains) returned no accessible Tier 1/2 results — actual hits were peer-reviewed literature and clinical-trial registries outside the permitted whitelist, so they are not cited. Per instructions, the note below is grounded primarily in the supplied Hindu BusinessLine article (Tier 4), which is itself the primary source for this current-affairs item.
The Alarming Rise of Medicalisation in India — UPSC Study Note
1. At a Glance
- Medicalisation refers to treating non-medical conditions (like body weight/lifestyle patterns) as medical problems requiring drugs or clinical intervention, rather than addressing root behavioural/structural causes [S1].
- India's obesity-metabolic disease burden (diabetes, hypertension, fatty liver, dyslipidaemia) is rising sharply, and the policy/market response is trending toward pharmaceutical fixes (e.g., anti-obesity drugs) rather than food-systems reform [S1].
- Relevant for GS-II (health policy, governance) and GS-III (science-tech, economy) — tests ability to link corporate/employment practice, drug regulation, and public health policy.
- Illustrates the tension between individual-fitness framing (BMI-based corporate rules) and structural determinants (ultra-processed food proliferation, sedentary urban lifestyles) [S1].
2. Why in the News
- Air India announced potential pay cuts/de-rostering for cabin crew with higher Body Mass Index (BMI), framed as a fitness/operational-safety measure [S1].
- This coincided with semaglutide (a GLP-1 anti-obesity drug) going off-patent, with nearly 40 products entering the Indian market in the same week — raising concern that medicalisation (drug-based fixes) is being normalised over addressing structural causes of obesity [S1].
3. Background & Evolution
- Rising overweight/obesity and metabolic disease prevalence in India has been documented over the past decade, moving from a "lifestyle disease of affluence" to a mass public health concern spanning urban and rural populations [S1].
- Parallel global trend: semaglutide was developed and marketed first for type-2 diabetes (as Ozempic) before its anti-obesity indication (as Wegovy) gained traction — its 2026 patent expiry in India opened the market to multiple generic/biosimilar entrants [S1].
- Corporate BMI-linked employment policies (as in aviation) mark a new front where medicalised, individual-blame framing enters workplace regulation [S1].
4. Core Static Facts
| Item | Detail |
|---|---|
| Trigger event | Air India's BMI-linked crew policy (pay cuts/de-rostering) [S1] |
| Drug in focus | Semaglutide (GLP-1 receptor agonist), anti-obesity use |
| Patent status | Went off-patent in India in the reported week (April 2026) [S1] |
| Market entrants | ~40 new semaglutide-based products entered Indian market [S1] |
| Conditions cited | Obesity, diabetes, hypertension, fatty liver disease, dyslipidaemia [S1] |
| Reported burden | "Nearly a quarter" of Indians overweight/obese; "1 in 10" adults diabetic; "1 in 3" hypertensive; "substantial proportion" with fatty liver [S1] |
| Cited causes | Ultra-processed/HFSS (high fat-salt-sugar) foods, sedentary urban lifestyles, shrinking open spaces, chronic stress, alcohol, poor sleep, South Asian genetic predisposition to central adiposity [S1] |
| Author/expert | Dr. Chandrakant Lahariya, cardiometabolic physician & health policy expert (article author) [S1] |
5. Multi-Dimensional Analysis
Social - Corporate BMI policies risk stigmatising employees rather than addressing systemic causes — raises equity/discrimination concerns in the workplace [S1]. - Childhood obesity is rising rapidly, indicating an intergenerational public health crisis, not just an adult lifestyle issue [S1].
Economic - A ~40-product surge in the anti-obesity drug market signals a shift toward a pharmaceutical solution economy, with commercial incentives around patent expiry rather than preventive public health investment [S1]. - Employment-linked BMI policy (pay cuts) directly monetises a health metric, shifting cost of "fitness" onto employees rather than systemic food/urban-planning reform [S1].
Scientific/Technological - Semaglutide's off-patent status is expected to sharply lower cost and increase access to anti-obesity pharmacotherapy in India [S1]. - Genetic predisposition among Indians/South Asians toward abdominal fat accumulation despite normal BMI ("thin-fat phenotype") complicates BMI-only screening/policy tools [S1].
Ethical/Governance - Core critique: medicalisation (drugs, BMI-based HR rules) is drawing attention away from ultra-processed food proliferation — the more fundamental, upstream driver — reflecting weak regulatory will on food environments [S1]. - Raises questions on using a narrow biomarker (BMI) as a proxy for fitness/competence in employment contexts.
Administrative - No single ministry/regulator was cited in the article as governing HFSS/ultra-processed food labelling or drug-market entry timing — signals a regulatory gap in coordinated obesity policy (food regulation vs. drug approval vs. labour policy) [S1].
6. Recent Developments (last 12-18 months)
- April 2026: Air India's BMI-linked crew fitness policy announced, triggering public debate [S1].
- April 2026 (same week): Semaglutide's patent expiry in India, with ~40 new anti-obesity products launched [S1].
7. Prelims Hooks
- Medicalisation = framing non-medical/lifestyle issues as conditions needing clinical/drug treatment [S1].
- Semaglutide is a GLP-1 receptor agonist, originally for type-2 diabetes, later approved for weight management [S1].
- Semaglutide went off-patent in India in the week of the reported Air India controversy (April 2026) [S1].
- Nearly 40 semaglutide-based products entered the Indian market post-patent expiry [S1].
- Air India's controversial move: pay cuts/de-rostering for cabin crew based on BMI [S1].
- Roughly 1 in 4 Indians are overweight/obese per the article's cited figures [S1].
- Roughly 1 in 10 Indian adults have diabetes; 1 in 3 have hypertension (as cited in the article) [S1].
- South Asians/Indians show a genetic predisposition to excess body fat despite lean appearance — sometimes termed the "thin-fat" phenotype [S1].
- HFSS = High Fat, Salt, and Sugar content foods — a recurring regulatory/nutrition-labelling term [S1].
- Ultra-processed food proliferation is cited as a key, under-addressed driver of the obesity epidemic, contrasted with drug-based solutions [S1].
- BMI (Body Mass Index) is the metric used in the Air India policy — a screening tool, not a diagnostic one, criticised for limited applicability to Indian body composition [S1].
8. Mains Relevance
- GS-II: Health — issues relating to development and management of social sector/services (health); governance issues in food regulation and labour policy.
- GS-III: Science and Technology — developments in biotechnology/pharmaceuticals; Economy — employment and labour welfare.
- Possible question stems: 1. "Discuss the concept of 'medicalisation' in the context of India's rising obesity burden. Does reliance on pharmacological solutions risk neglecting structural determinants of health?" (GS-II) 2. "Critically examine the adequacy of India's regulatory framework for ultra-processed foods in addressing the obesity and non-communicable disease burden." (GS-II/III) 3. "BMI-linked employment policies raise ethical and equity concerns. Discuss with reference to recent corporate practices in India." (GS-IV/GS-II)
9. Related Topics to Study Next
- NCD (Non-Communicable Disease) burden in India — obesity is one strand of the broader NCD policy challenge.
- FSSAI and food labelling regulations (HFSS norms) — the regulatory gap the article highlights.
- National Nutrition Mission / POSHAN Abhiyaan — India's preventive nutrition policy architecture.
- Right to Health / workplace discrimination law — legal angle on BMI-based employment decisions.
- Pharma patent regime (TRIPS, Indian Patents Act, 1970) — relevant to semaglutide's patent expiry and generic entry.
- Urbanisation and lifestyle disease linkage — sedentary lifestyle, urban planning, and public health.
- Global obesity trends (WHO reports) — comparative international context for benchmarking India's burden.
10. Common Errors / Trap Areas
- Do not confuse semaglutide (GLP-1 receptor agonist, originally anti-diabetic) with insulin or other unrelated diabetes drugs.
- Do not assume a specific ministry (e.g., MoHFW or FSSAI) issued the Air India BMI policy — it is a corporate/airline HR decision, not a government regulation.
- Avoid citing exact NFHS/ICMR-INDIAB percentage figures with false precision — the article uses approximate phrasing ("nearly a quarter," "one in 10," "one in three"); precise official figures were not retrievable from whitelisted sources in this session and should be verified separately before use in answers.
- Don't treat "medicalisation" as synonymous with "healthcare access improvement" — it specifically denotes an over-reliance on clinical/drug labels for social or lifestyle issues, often used critically.
- Avoid assuming semaglutide's patent expiry is India-specific policy — it is a global pharmaceutical patent-cycle event with Indian market implications.
11. Sources
- [S1] The alarming rise of medicalisation in India — The Hindu — https://www.thehindu.com/todays-paper/2026-04-15/th_international/articleGA7FRQ4HR-14243749.ece — (tier: 4)